in vitro News and Research

RSS

Breast milk may protect premature infants from intestinal destruction

Premature infants are at increased risk for a potentially lethal gastrointestinal disease called necrotizing enterocolitis, or NEC.

9 Sep 2014

Nosopharm reports findings on Odilorhabdins that has potential to combat antibiotic resistance

Nosopharm, a specialist in the research and development of new anti-infective drugs, announces today its in vitro and in vivo findings for a novel antibacterial class, Odilorhabdins, which has the potential to combat antibiotic resistance.

4 Sep 2014

Exposure to certain phenols during pregnancy may disrupt growth of boys

A research consortium bringing together teams from Inserm, the Nancy and Poitiers University Hospitals, and the Centers for Disease Control and Prevention (CDC, Atlanta, USA), and coordinated by the Inserm and University of Grenoble Environmental Epidemiology team (Unit 823), has just published an epidemiological study indicating that exposure to certain phenols during pregnancy, especially parabens and triclosan, may disrupt growth of boys during foetal growth and the first years of life.

4 Sep 2014

Clinical studies to treat unmet medical need post-transplantation

A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function

3 Sep 2014

BioLegend acquires shares of Covance Antibody Services

BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance, located in Dedham, Massachusetts, on August 29, 2014.

From BioLegend 2 Sep 2014

Cepheid releases Xpert Flu/RSV XC for accurate determination of Flu A, Flu B and RSV infection

Cepheid announced today the release of Xpert® Flu/RSV XC, an on-demand molecular test for rapid, accurate and reliable determination of Flu A, Flu B, and differentiation of RSV infection.

2 Sep 2014

Two fully automated molecular testing systems for blood and plasma donor screening launched by Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening, in markets accepting the CE mark. The cobas 6800/8800 Systems offer the fastest time to results with the highest throughput available, along with the longest walk-away time, enabling laboratory staff to drive increased workflow efficiencies, while adapting to their ever-changing testing demands.

From Roche Sequencing and Life Science 2 Sep 2014

Researchers find way to take pediatric patient's skin cells

Researchers have found a way to take a pediatric patient's skin cells, reprogram the skin cells to function as heart valvular cells, and then use the cells as part of a tissue-engineered pulmonary valve. A proof of concept study in the September 2014 issue of The Annals of Thoracic Surgery provides more detail on this scientific development.

2 Sep 2014

Study for better understanding of neural circuitry and dynamic mechanisms controlling memory

A study just published in the prestigious Nature Neuroscience journal by, Sylvain Williams, PhD, and his team, of the Research Centre of the Douglas Mental Health University Institute and McGill University, opens the door towards better understanding of the neural circuitry and dynamic mechanisms controlling memory as well of the role of an essential element of the hippocampus - a sub-region named the subiculum.

1 Sep 2014

ESC launches first recommendations on use of all new oral anticoagulants in pulmonary embolism

The first recommendations on the use of all new oral anticoagulants in pulmonary embolism are published today in new ESC Guidelines.

30 Aug 2014

Study compares FK506 and rapamycin for Schwann cell migration, peripheral nerve regeneration

FK506 possesses a well-studied neuroregenerative effect, stimulating neurite extension in the presence of nerve growth factor in vitro, and enhancing nerve regeneration following nerve crush injury and isografting.

30 Aug 2014

New adhesive method for repairing sciatic nerves

When repairing nerves with adhesives, most researchers place glue directly on the nerve stumps, but this method does not fix the nerve ends well and allows glue to easily invade the nerve ends.

29 Aug 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Aug 2014

Versatile nanoparticles offer wide variety of diagnostic and therapeutic applications

Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer.

27 Aug 2014

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans.

26 Aug 2014

Ruthigen gets DMC recommendation to begin RUT58-60 Phase 1/2 clinical trial

Ruthigen Inc., a biopharmaceutical company focused on improving patient outcomes and reducing healthcare costs in invasive procedures, has announced that its lead drug candidate, RUT58-60, has received a recommendation from the Data Monitoring Committee to begin enrolling patients in the Company's planned Phase 1/2 clinical trial.

26 Aug 2014

Researchers develop new integrated approach to pinpoint genetic "drivers" of cancer

UNC Lineberger Comprehensive Cancer Center researchers have developed a new integrated approach to pinpoint the genetic "drivers" of cancer, uncovering eight genes that could be viable for targeted breast cancer therapy.

25 Aug 2014

Researchers find more selective therapies for cancer

Thanks to important discoveries in basic and clinical research and technological advances, the fight against cancer has mobilized into a complex offensive spanning multiple fronts.

25 Aug 2014

SeraCare Life Sciences announces launch of new ACCURUN 501 C. difficile Control

SeraCare Life Sciences, a provider of high-quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, today announced the launch of its new ACCURUN 501 C. difficile Control – the company's first molecular control product targeting hospital acquired infections.

23 Aug 2014

Allen Institute for Brain Science welcomes visiting scientist engineer

The Allen Institute for Brain Science welcomes a visiting scientist from Harvard and a visiting engineer from Georgia Tech: Sharad Ramanathan, Ph.D.; and Craig Forest, Ph.D. Both Ramanathan and Forest will bring their distinct knowledge and backgrounds to the expanding scientific teams at the Allen Institute.

22 Aug 2014